Contact
searchSearch
HMP Global

Lymphoma, Leukemia & Myeloma Network

Featured

Quiz
GPRC5D-Targeted CAR T-Cell Therapy for Multiple Myeloma
04/02/2025
What was the reported hematologic toxicity profile of GPRC5D-targeted CAR T-cell therapy among patients with multiple myeloma?
What was the reported hematologic toxicity profile of GPRC5D-targeted CAR T-cell therapy among patients with multiple myeloma?
What was the reported...
04/02/2025
Oncology
From Oncology
News
Modakafusp Alfa Demonstrates Antitumor Activity Among Patients With Relapsed/Refractory Multiple Myeloma
04/02/2025
At a tolerable and safe dose, the anti-CD38 antibody, modakafusp alfa demonstrated decreased tumor activity and immune activation among patients with relapsed/refractory multiple myeloma.
At a tolerable and safe dose, the anti-CD38 antibody, modakafusp alfa demonstrated decreased tumor activity and immune activation among patients with relapsed/refractory multiple myeloma.
At a tolerable and safe dose,...
04/02/2025
Oncology
From Oncology
News
Quadruplet Therapy Demonstrates Efficacy for Treatment of Transplant-Ineligible Newly Diagnosed Multiple Myeloma
04/02/2025
Quadruplet therapy with isatuximab, weekly bortezomib, lenalidomide, and limited dexamethasone demonstrated safety and efficacy for older patients with transplant-ineligible MM in a phase 2 clinical trial.
Quadruplet therapy with isatuximab, weekly bortezomib, lenalidomide, and limited dexamethasone demonstrated safety and efficacy for older patients with transplant-ineligible MM in a phase 2 clinical trial.
Quadruplet therapy with...
04/02/2025
Oncology
From Oncology
News
Co-Occurrence of High-Risk Cytogenetic Abnormalities as a Predictive Marker for Multiple Myeloma
04/02/2025
The presence of 2 or more high-risk cytogenetic abnormalities among patients with multiple myeloma was associated with poor survival outcomes, according to a systematic review and meta-analysis.
The presence of 2 or more high-risk cytogenetic abnormalities among patients with multiple myeloma was associated with poor survival outcomes, according to a systematic review and meta-analysis.
The presence of 2 or more...
04/02/2025
Oncology
From Oncology
News
Lisocabtagene Maraleucel Demonstrates Potential Improved Efficacy Over Mosunetuzumab for Third-Line or Later Treatment of R/R Follicular Lymphoma
03/25/2025
Lisocabtagene maraleucel demonstrated potential improved patient outcomes compared with mosunetuzumab for patients with R/R FL who have had 2 or more lines of prior therapy, according to an unanchored matching-adjusted indirect comparison.
Lisocabtagene maraleucel demonstrated potential improved patient outcomes compared with mosunetuzumab for patients with R/R FL who have had 2 or more lines of prior therapy, according to an unanchored matching-adjusted indirect comparison.
Lisocabtagene maraleucel...
03/25/2025
Oncology
From Oncology
News
Real-World Comparison of Dasatinib and Nilotinib as Second-Line Therapy for Chronic Phase Chronic Myeloid Leukemia
03/25/2025
According to results from a real-world retrospective analysis, dasatinib and nilotinib demonstrate comparable efficacy and tolerability among patients with chronic myeloid leukemia in chronic phase.
According to results from a real-world retrospective analysis, dasatinib and nilotinib demonstrate comparable efficacy and tolerability among patients with chronic myeloid leukemia in chronic phase.
According to results from a...
03/25/2025
Oncology
From Oncology
News
Inaticabtagene Autoleucel Demonstrates Efficacy and Tolerability for Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia
03/25/2025
Inaticabtagene autoleucel treatment for patients with relapsed/refractory B-cell acute lymphoblastic leukemia showed efficacy and durability in a phase 2 clinical trial.
Inaticabtagene autoleucel treatment for patients with relapsed/refractory B-cell acute lymphoblastic leukemia showed efficacy and durability in a phase 2 clinical trial.
Inaticabtagene autoleucel...
03/25/2025
Oncology
From Oncology
News
Effect of Timing of Bispecific Antibody Treatment for Patients With B-Cell Lymphomas Relapsing After CAR-T
03/24/2025
Following CAR-T therapy relapse, study findings suggest the timing of bispecific antibody treatment administration may be associated with improved responses among patients with B-cell lymphomas.
Following CAR-T therapy relapse, study findings suggest the timing of bispecific antibody treatment administration may be associated with improved responses among patients with B-cell lymphomas.
Following CAR-T therapy relapse,...
03/24/2025
Oncology
From Oncology
News
Real-World Efficacy of Asciminib in Chronic Myeloid Leukemia After Multiple Tyrosine Kinase Inhibitors
03/24/2025
For patients with chronic myeloid leukemia in chronic phase previously treated with tyrosine kinase inhibitors, asciminib demonstrated efficacy and tolerability in a real-world setting.
For patients with chronic myeloid leukemia in chronic phase previously treated with tyrosine kinase inhibitors, asciminib demonstrated efficacy and tolerability in a real-world setting.
For patients with chronic...
03/24/2025
Oncology
From Oncology
C. Ola Landgren, MD, PhD
Videos
Updates in Frontline Therapies for Patients With Transplant-Ineligible Multiple Myeloma
03/21/2025
C. Ola Landgren, MD, PhD shares updates on improvements in cancer outcomes, including prolonged survival and tolerability, for patients with newly diagnosed multiple myeloma who are transplant-ineligible.
C. Ola Landgren, MD, PhD shares updates on improvements in cancer outcomes, including prolonged survival and tolerability, for patients with newly diagnosed multiple myeloma who are transplant-ineligible.
C. Ola Landgren, MD, PhD shares...
03/21/2025
Oncology
From Oncology
Michael Green, PhD
Conference Coverage
Potential Impact of Classification of R/R Diffuse Large B-Cell Lymphoma Microenvironment Archetypes on Patient Treatment and Outcomes
03/17/2025
Michael Green, PhD, discusses relapsed/refractory diffuse large B-cell lymphoma microenvironment archetypes and the effect of immunomodulatory and cellular therapies on patient outcomes.
Michael Green, PhD, discusses relapsed/refractory diffuse large B-cell lymphoma microenvironment archetypes and the effect of immunomodulatory and cellular therapies on patient outcomes.
Michael Green, PhD, discusses...
03/17/2025
Oncology
From Oncology

Interactive Features

Quiz
GPRC5D-Targeted CAR T-Cell Therapy for Multiple Myeloma
04/02/2025
What was the reported hematologic toxicity profile of GPRC5D-targeted CAR T-cell therapy among patients with multiple myeloma?
What was the reported hematologic toxicity profile of GPRC5D-targeted CAR T-cell therapy among patients with multiple myeloma?
What was the reported...
04/02/2025
Oncology
Quiz
Efficacy of Rituximab Maintenance After ASCT Among Patients With Mantle Cell Lymphoma
07/09/2024
True or False: According to a 7.5-year follow-up of the LYMA trial, standard-of-care therapy of rituximab maintenance following autologous stem cell transplantation continued to demonstrate benefits to efficacy and safety outcomes among...
True or False: According to a 7.5-year follow-up of the LYMA trial, standard-of-care therapy of rituximab maintenance following autologous stem cell transplantation continued to demonstrate benefits to efficacy and safety outcomes among...
True or False: According to a...
07/09/2024
Lymphoma, Leukemia & Myeloma Network
Quiz
Overall Response Rate of Tafasitamab Plus Lenalidomide for Patients With R/R Diffuse Large B-Cell Lymphoma
06/14/2023
Quiz: According to final results of the phase 2 L-MIND study, what was the overall response rate of tafasitamab plus lenalidomide followed by long-term tafasitamab monotherapy for patients with R/R diffuse large B-cell lymphoma?
Quiz: According to final results of the phase 2 L-MIND study, what was the overall response rate of tafasitamab plus lenalidomide followed by long-term tafasitamab monotherapy for patients with R/R diffuse large B-cell lymphoma?
Quiz: According to final results...
06/14/2023
Oncology
Quiz
Radiomics Features and Prediction of Outcomes for Aggressive B-Cell Lymphoma
06/09/2023
True or False In a study assessing the predictive quality of clinical, molecular genotype, and radiomics features for aggressive B-cell lymphoma, results indicated that radiomics features extracted from baseline 18F-FDG PET/CT scans...
True or False In a study assessing the predictive quality of clinical, molecular genotype, and radiomics features for aggressive B-cell lymphoma, results indicated that radiomics features extracted from baseline 18F-FDG PET/CT scans...
True or False In a study...
06/09/2023
Oncology

Insights

C. Ola Landgren, MD, PhD
Videos
Updates in Frontline Therapies for Patients With Transplant-Ineligible Multiple Myeloma
03/21/2025
C. Ola Landgren, MD, PhD shares updates on improvements in cancer outcomes, including prolonged survival and tolerability, for patients with newly diagnosed multiple myeloma who are transplant-ineligible.
C. Ola Landgren, MD, PhD shares updates on improvements in cancer outcomes, including prolonged survival and tolerability, for patients with newly diagnosed multiple myeloma who are transplant-ineligible.
C. Ola Landgren, MD, PhD shares...
03/21/2025
Oncology
Michael Green, PhD
Conference Coverage
Potential Impact of Classification of R/R Diffuse Large B-Cell Lymphoma Microenvironment Archetypes on Patient Treatment and Outcomes
03/17/2025
Michael Green, PhD, discusses relapsed/refractory diffuse large B-cell lymphoma microenvironment archetypes and the effect of immunomodulatory and cellular therapies on patient outcomes.
Michael Green, PhD, discusses relapsed/refractory diffuse large B-cell lymphoma microenvironment archetypes and the effect of immunomodulatory and cellular therapies on patient outcomes.
Michael Green, PhD, discusses...
03/17/2025
Oncology
Rami Komrokji, MD
Conference Coverage
Risk Stratification and Treatment Strategies for High-Risk Myelodysplastic Syndromes
03/05/2025
At the 2025 Lymphoma, Leukemia & Myeloma Winter Symposium, Rami Komrokji, MD discusses the latest updates in risk classification, standard of care, and treatment strategies for myelodysplastic syndromes.
At the 2025 Lymphoma, Leukemia & Myeloma Winter Symposium, Rami Komrokji, MD discusses the latest updates in risk classification, standard of care, and treatment strategies for myelodysplastic syndromes.
At the 2025 Lymphoma, Leukemia &...
03/05/2025
Oncology
Izidore Lossos, MD
Conference Coverage
Recent Advancements in Treatment of Mantle Cell Lymphoma and Marginal Zone Lymphoma
03/05/2025
At the 2025 Lymphoma, Leukemia & Myeloma Winter Symposium, Izidore Lossos, MD shares insights into treatment strategies for patients with mantle cell lymphoma and marginal zone lymphoma.
At the 2025 Lymphoma, Leukemia & Myeloma Winter Symposium, Izidore Lossos, MD shares insights into treatment strategies for patients with mantle cell lymphoma and marginal zone lymphoma.
At the 2025 Lymphoma, Leukemia &...
03/05/2025
Oncology
Craig Moskowitz, MD
Conference Coverage
Updates in Standard of Care and Disease Management Strategies for Patients With Hodgkin Lymphoma
03/05/2025
Craig Moskowitz, MD discusses updates in the treatment and management of Hodgkin lymphoma for patients in various disease stages at the 2025 Lymphoma, Leukemia & Myeloma Winter Symposium.
Craig Moskowitz, MD discusses updates in the treatment and management of Hodgkin lymphoma for patients in various disease stages at the 2025 Lymphoma, Leukemia & Myeloma Winter Symposium.
Craig Moskowitz, MD discusses...
03/05/2025
Oncology
Andrew Evens, DO, MBA, MSc
Videos
Therapeutic Breakthroughs and Latest Updates for the Treatment of Follicular Lymphoma
02/28/2025
Andrew Evens, DO, MBA, MSc shared the latest updates and therapeutic advancements for the treatment of follicular lymphoma at the 2025 Lymphoma, Leukemia & Myeloma Winter Symposium.
Andrew Evens, DO, MBA, MSc shared the latest updates and therapeutic advancements for the treatment of follicular lymphoma at the 2025 Lymphoma, Leukemia & Myeloma Winter Symposium.
Andrew Evens, DO, MBA, MSc...
02/28/2025
Oncology
Joanna Rhodes, MD, MSCE
Videos
Recent Advancements in Frontline Therapy for Patients with R/R Follicular Lymphoma
02/28/2025
Joanna Rhodes, MD, MSCE discusses advances in frontline treatment, including bispecific antibodies and T-cell therapies, for patients with follicular lymphoma at the 20205 Lymphoma, Leukemia & Myeloma Winter Symposium.
Joanna Rhodes, MD, MSCE discusses advances in frontline treatment, including bispecific antibodies and T-cell therapies, for patients with follicular lymphoma at the 20205 Lymphoma, Leukemia & Myeloma Winter Symposium.
Joanna Rhodes, MD, MSCE...
02/28/2025
Oncology
Fadi Haddad, MD
Videos
Latest Strategies for Treating Patients With Chronic Myeloid Leukemia
02/24/2025
Fadi Haddad, MD, shares the most recent updates in the treatment of patients with chronic myeloid leukemia at the 2025 LL&M Winter Symposium in Miami, Florida.
Fadi Haddad, MD, shares the most recent updates in the treatment of patients with chronic myeloid leukemia at the 2025 LL&M Winter Symposium in Miami, Florida.
Fadi Haddad, MD, shares the most...
02/24/2025
Oncology
John Allan, MD
Videos
Novel Targeted Therapies for Patients with Chronic Lymphocytic Leukemia
02/24/2025
John Allan, MD discusses new approaches for chronic lymphocytic leukemia, including CAR T-cell therapies, bispecific antibodies, and BTK degraders, at the 2025 LL&M Winter Symposium.
John Allan, MD discusses new approaches for chronic lymphocytic leukemia, including CAR T-cell therapies, bispecific antibodies, and BTK degraders, at the 2025 LL&M Winter Symposium.
John Allan, MD discusses new...
02/24/2025
Oncology
Victor Jimenez-Zepeda, MD
Videos
Advancements in Treating Patients with Precursor Disorders of Multiple Myeloma
02/24/2025
Victor Jimenez-Zepeda, MD, discusses updates in clinical trials for treatment of smoldering multiple myeloma and monoclonal gammopathy of undetermined significance prior to development of symptomatic multiple myeloma.
Victor Jimenez-Zepeda, MD, discusses updates in clinical trials for treatment of smoldering multiple myeloma and monoclonal gammopathy of undetermined significance prior to development of symptomatic multiple myeloma.
Victor Jimenez-Zepeda, MD,...
02/24/2025
Oncology

Meeting Materials

Real-world Experience with Isatuximab in Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM): IONA-MM First Interim Analysis
Introduction:
11/04/2022
Developing an Ontology-Based Platform to Detect Serine Protease Involvement in BALT Lymphoma Patients with COVID-19 & Connect Them to Clinical Trials
Introduction:
11/04/2022
The Tree That Hides the Forest: An Unfortunate Story of T/NK Lymphoma
Introduction: NK/T lymphoma is a rare type of non-Hodgkin's lymphoma [1,2]. It is a clinical entity that manifests itself essentially by a necrosis that usually starts in the nasal caviti...
11/04/2022

In the News

News
Modakafusp Alfa Demonstrates Antitumor Activity Among Patients With Relapsed/Refractory Multiple Myeloma
04/02/2025
At a tolerable and safe dose, the anti-CD38 antibody, modakafusp alfa demonstrated decreased tumor activity and immune activation among patients with relapsed/refractory multiple myeloma.
At a tolerable and safe dose, the anti-CD38 antibody, modakafusp alfa demonstrated decreased tumor activity and immune activation among patients with relapsed/refractory multiple myeloma.
At a tolerable and safe dose,...
04/02/2025
Oncology
News
Quadruplet Therapy Demonstrates Efficacy for Treatment of Transplant-Ineligible Newly Diagnosed Multiple Myeloma
04/02/2025
Quadruplet therapy with isatuximab, weekly bortezomib, lenalidomide, and limited dexamethasone demonstrated safety and efficacy for older patients with transplant-ineligible MM in a phase 2 clinical trial.
Quadruplet therapy with isatuximab, weekly bortezomib, lenalidomide, and limited dexamethasone demonstrated safety and efficacy for older patients with transplant-ineligible MM in a phase 2 clinical trial.
Quadruplet therapy with...
04/02/2025
Oncology
News
Co-Occurrence of High-Risk Cytogenetic Abnormalities as a Predictive Marker for Multiple Myeloma
04/02/2025
The presence of 2 or more high-risk cytogenetic abnormalities among patients with multiple myeloma was associated with poor survival outcomes, according to a systematic review and meta-analysis.
The presence of 2 or more high-risk cytogenetic abnormalities among patients with multiple myeloma was associated with poor survival outcomes, according to a systematic review and meta-analysis.
The presence of 2 or more...
04/02/2025
Oncology
News
Lisocabtagene Maraleucel Demonstrates Potential Improved Efficacy Over Mosunetuzumab for Third-Line or Later Treatment of R/R Follicular Lymphoma
03/25/2025
Lisocabtagene maraleucel demonstrated potential improved patient outcomes compared with mosunetuzumab for patients with R/R FL who have had 2 or more lines of prior therapy, according to an unanchored matching-adjusted indirect comparison.
Lisocabtagene maraleucel demonstrated potential improved patient outcomes compared with mosunetuzumab for patients with R/R FL who have had 2 or more lines of prior therapy, according to an unanchored matching-adjusted indirect comparison.
Lisocabtagene maraleucel...
03/25/2025
Oncology
News
Real-World Comparison of Dasatinib and Nilotinib as Second-Line Therapy for Chronic Phase Chronic Myeloid Leukemia
03/25/2025
According to results from a real-world retrospective analysis, dasatinib and nilotinib demonstrate comparable efficacy and tolerability among patients with chronic myeloid leukemia in chronic phase.
According to results from a real-world retrospective analysis, dasatinib and nilotinib demonstrate comparable efficacy and tolerability among patients with chronic myeloid leukemia in chronic phase.
According to results from a...
03/25/2025
Oncology
News
Inaticabtagene Autoleucel Demonstrates Efficacy and Tolerability for Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia
03/25/2025
Inaticabtagene autoleucel treatment for patients with relapsed/refractory B-cell acute lymphoblastic leukemia showed efficacy and durability in a phase 2 clinical trial.
Inaticabtagene autoleucel treatment for patients with relapsed/refractory B-cell acute lymphoblastic leukemia showed efficacy and durability in a phase 2 clinical trial.
Inaticabtagene autoleucel...
03/25/2025
Oncology
News
Effect of Timing of Bispecific Antibody Treatment for Patients With B-Cell Lymphomas Relapsing After CAR-T
03/24/2025
Following CAR-T therapy relapse, study findings suggest the timing of bispecific antibody treatment administration may be associated with improved responses among patients with B-cell lymphomas.
Following CAR-T therapy relapse, study findings suggest the timing of bispecific antibody treatment administration may be associated with improved responses among patients with B-cell lymphomas.
Following CAR-T therapy relapse,...
03/24/2025
Oncology
News
Real-World Efficacy of Asciminib in Chronic Myeloid Leukemia After Multiple Tyrosine Kinase Inhibitors
03/24/2025
For patients with chronic myeloid leukemia in chronic phase previously treated with tyrosine kinase inhibitors, asciminib demonstrated efficacy and tolerability in a real-world setting.
For patients with chronic myeloid leukemia in chronic phase previously treated with tyrosine kinase inhibitors, asciminib demonstrated efficacy and tolerability in a real-world setting.
For patients with chronic...
03/24/2025
Oncology
News
Brentuximab Vedotin Plus Lenalidomide and Rituximab Improves Survival For Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
03/17/2025
For patients with relapsed/refractory diffuse large B-cell lymphoma, brentuximab vedotin plus lenalidomide and rituximab was associated with improved survival rates and tolerability, according to results from a phase 3 study.
For patients with relapsed/refractory diffuse large B-cell lymphoma, brentuximab vedotin plus lenalidomide and rituximab was associated with improved survival rates and tolerability, according to results from a phase 3 study.
For patients with...
03/17/2025
Oncology
News
Denileukin Diftitox-CXDL Demonstrates Efficacy for Relapsed/Refractory Cutaneous T-Cell Lymphoma
03/17/2025
A recent phase 3 trial evaluating the use of denileukin diftitox-CXDL for relapsed/refractory cutaneous T-cell lymphoma demonstrated reduced skin tumor burden and promising tolerability.
A recent phase 3 trial evaluating the use of denileukin diftitox-CXDL for relapsed/refractory cutaneous T-cell lymphoma demonstrated reduced skin tumor burden and promising tolerability.
A recent phase 3 trial...
03/17/2025
Oncology

Latest Podcasts

Podcasts
Dr Leonard Shares Highlights to Expect at the 2020 Lymphoma, Leukemia & Myeloma Congress
10/19/2020
John Leonard, MD, discusses what to expect at the virtual 2020 Lymphoma, Leukemia & Myeloma Congress taking place October 21-24, 2020.
John Leonard, MD, discusses what to expect at the virtual 2020 Lymphoma, Leukemia & Myeloma Congress taking place October 21-24, 2020.
John Leonard, MD, discusses what...
10/19/2020
Oncology
What to Expect at the Non-Malignant Hematology Workshop at Lymphoma, Leukemia & Myeloma Congress
Podcasts
What to Expect at the Non-Malignant Hematology Workshop at Lymphoma, Leukemia & Myeloma Congress
08/24/2020
James B. Bussel, MD, gives an overview of what to expect at the brand new Non-Malignant Hematology Workshop and how the content is critical for hematology and oncology practice.
James B. Bussel, MD, gives an overview of what to expect at the brand new Non-Malignant Hematology Workshop and how the content is critical for hematology and oncology practice.
James B. Bussel, MD, gives an...
08/24/2020
Oncology
Podcasts
Seattle Children's Hospital Leukemia Program Offers Multidisciplinary Care to Underserved Population
06/19/2018
Todd Cooper, DO, discusses a new program launched at The Seattle Children's Hospital for patients with high-risk leukemia.
Todd Cooper, DO, discusses a new program launched at The Seattle Children's Hospital for patients with high-risk leukemia.
Todd Cooper, DO, discusses a new...
06/19/2018
Oncology

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2025 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use